Current Breast Cancer Reports

, Volume 4, Issue 3, pp 207–215 | Cite as

Tamoxifen versus Raloxifene versus Exemestane for Chemoprevention

Risk, Prevention, and Screening (MC Liu, Section Editor)


Clinical trial data on selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) have demonstrated reduced breast cancer incidence in the prevention setting among high-risk women. We conducted an extensive review of clinical trials and recent published reports of barriers to uptake of breast cancer chemoprevention, to provide health care professionals with information to improve decision making regarding chemoprevention. Despite the positive results of these trials, uptake of chemoprevention has been low due to barriers in identifying high-risk women, lack of understanding of risks and benefits, as well as concerns about side effects. Interventions designed to increase uptake have met with limited success. Clinicians can support women in informed decision making about SERMs and AIs by effectively communicating breast cancer risk and enhancing knowledge about the risks and benefits of chemoprevention. Promoting uptake and adherence to chemoprevention holds promise for reducing the public health burden of this disease.


Breast cancer Chemoprevention Selective estrogen receptor modulator SERM Aromatase inhibitor AI Prevention Risk 


Recently published papers of particular interest have been highlighted as: • Of importance

  1. 1.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.PubMedCrossRefGoogle Scholar
  2. 2.
    Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95:526–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2010;28:3090–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Ravdin PM. The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention. Cancer Prev Res. 2010;3:686–8.CrossRefGoogle Scholar
  6. 6.
    • Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91. This is the first chemoprevention trial of an aromatase inhibitor in high-risk postmenopausal women. The results showed a 65 % relative risk reduction in the incidence of invasive breast cancer with exemestane for 5 years, as compared with a placebo.PubMedCrossRefGoogle Scholar
  7. 7.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99:283–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007;99:727–37.PubMedCrossRefGoogle Scholar
  10. 10.
    Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272–82.PubMedCrossRefGoogle Scholar
  11. 11.
    Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA. 1999;281:2189–97.PubMedCrossRefGoogle Scholar
  12. 12.
    Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–37.PubMedCrossRefGoogle Scholar
  14. 14.
    Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362:686–96.PubMedCrossRefGoogle Scholar
  15. 15.
    LaCroix AZ, Powles T, Osborne CK, et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010;102:1706–15.PubMedCrossRefGoogle Scholar
  16. 16.
    Cummings SR, McClung M, Reginster JY, et al. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res. 2011;26:397–404.PubMedCrossRefGoogle Scholar
  17. 17.
    Becker C. Another selective estrogen-receptor modulator for osteoporosis. N Engl J Med. 2010;362:752–4.PubMedCrossRefGoogle Scholar
  18. 18.
    • Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res. 2010;3:696–706. Updated results from the STAR trial demonstrated that raloxifene retained 76 % of the efficacy of tamoxifen in preventing invasive breast cancer with a more favorable side effect profile.CrossRefGoogle Scholar
  19. 19.
    Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol. 2005;23:1636–43.PubMedCrossRefGoogle Scholar
  20. 20.
    Cuzick J. Chemoprevention of breast cancer. Breast Cancer. 2008;15:10–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296–300.PubMedCrossRefGoogle Scholar
  22. 22.
    Richardson H, Johnston D, Pater J, Goss P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol. 2007;14:89–96.PubMedCrossRefGoogle Scholar
  23. 23.
    Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther. 2008;8:1377–85.PubMedCrossRefGoogle Scholar
  24. 24.
    NCI and the STELLAR trial. Lancet. 2007;369:2134.Google Scholar
  25. 25.
    • Waters EA, Cronin KA, Graubard BI, et al. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev. 2010;19:443–6. Using data from the National Health Interview Survery, this study reported the low prevalence of tamoxifen use among women without breast cancer since its approval by the FDA for breast cancer chemoprevention.PubMedCrossRefGoogle Scholar
  26. 26.
    Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007;99:1782–92.PubMedCrossRefGoogle Scholar
  28. 28.
    Matsuno RK, Costantino JP, Ziegler RG, et al. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst. 2011;103:951–61.PubMedCrossRefGoogle Scholar
  29. 29.
    Abu-Rustum NR, Herbolsheimer H. Breast cancer risk assessment in indigent women at a public hospital. Gynecol Oncol. 2001;81:287–90.PubMedCrossRefGoogle Scholar
  30. 30.
    Grann VR, Jacobson JS, Troxel AB, et al. Barriers to minority participation in breast carcinoma prevention trials. Cancer. 2005;104:374–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111–30.PubMedCrossRefGoogle Scholar
  32. 32.
    Guerra CE, Sherman M, Armstrong K. Diffusion of breast cancer risk assessment in primary care. J Am Board Fam Med. 2009;22:272–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Sabatino SA, McCarthy EP, Phillips RS, Burns RB. Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers. Cancer Detect Prev. 2007;31:375–83.PubMedCrossRefGoogle Scholar
  34. 34.
    • Owens WL, Gallagher TJ, Kincheloe MJ, Ruetten VL. Implementation in a large health system of a program to identify women at high risk for breast cancer. J Oncol Pract. 2011;7:85–8. This study implemented routine screening with the Gail model for high-risk women seen in a women's center. Over 15 % of women met high-risk criteria, but only 2 % of eligible women agreed to a SERM for chemoprevention.PubMedCrossRefGoogle Scholar
  35. 35.
    Dubin-Rhodin A, Greenlee H, Terry MB, et al. Development of the Breast Cancer Family-Based Intervention Trial (BFIT) database. Washington, DC: American Society of Preventive Oncology; 2012.Google Scholar
  36. 36.
    Bober SL, Hoke LA, Duda RB, et al. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol. 2004;22:4951–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Melnikow J, Paterniti D, Azari R, et al. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer. 2005;103:1996–2005.PubMedCrossRefGoogle Scholar
  38. 38.
    Taylor R, Taguchi K. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med. 2005;3:242–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Fagerlin A, Zikmund-Fisher BJ, Nair V, et al. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat. 2010;119:613–20.PubMedCrossRefGoogle Scholar
  40. 40.
    Metcalfe KA, Snyder C, Seidel J, et al. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer. 2005;4:97–103.PubMedCrossRefGoogle Scholar
  41. 41.
    Salant T, Ganschow PS, Olopade OI, Lauderdale DS. "Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med. 2006;21:779–85.PubMedCrossRefGoogle Scholar
  42. 42.
    Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001;8:580–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Stacey D, O'Connor AM, DeGrasse C, Verma S. Development and evaluation of a breast cancer prevention decision aid for higher-risk women. Health Expect. 2003;6:3–18.PubMedCrossRefGoogle Scholar
  44. 44.
    Day R, Ganz PA, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol. 1999;17:2659–69.PubMedGoogle Scholar
  45. 45.
    Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2742–51.PubMedCrossRefGoogle Scholar
  46. 46.
    Buzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7:633–43.PubMedCrossRefGoogle Scholar
  47. 47.
    Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559–70.PubMedCrossRefGoogle Scholar
  48. 48.
    Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–57.PubMedCrossRefGoogle Scholar
  49. 49.
    Kaplan CP, Haas JS, Perez-Stable EJ, et al. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med. 2005;41:7–15.PubMedCrossRefGoogle Scholar
  50. 50.
    Rondanina G, Puntoni M, Severi G, et al. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users. J Clin Oncol. 2008;26:1537–43.PubMedCrossRefGoogle Scholar
  51. 51.
    Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol. 2011;29:2327–33.PubMedCrossRefGoogle Scholar
  52. 52.
    Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res. 2011;4:1360–5.CrossRefGoogle Scholar
  53. 53.
    Dezentje VO, van Blijderveen NJ, Gelderblom H, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol. 2010;28:2423–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28:4120–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Veronesi A, Pizzichetta MA, Ferlante MA, et al. Tamoxifen as adjuvant after surgery for breast cancer and tamoxifen or placebo as chemoprevention in healthy women: different compliance with treatment. Tumori. 1998;84:372–5.PubMedGoogle Scholar
  57. 57.
    Land SR, Cronin WM, Wickerham DL, et al. Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the national surgical adjuvant breast and bowel project p-1 breast cancer prevention trial. Cancer Prev Res. 2011;4:1393–400.CrossRefGoogle Scholar
  58. 58.
    Moy B, Richardson H, Johnston D, et al. NCIC CTG MAP.3: enrollment and study drug adherence of ethnic minority women in a breast cancer prevention trial. Breast Cancer Res Treat. 2007;106:S141–2.Google Scholar
  59. 59.
    • Fagerlin A, Dillard AJ, Smith DM, et al. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. Breast Cancer Res Treat. 2011;127:681–8. This is a randomized controlled trial of a tailored on-line decision aid to inform women about breast cancer chemoprevention, which resulted in low SERM uptake.PubMedCrossRefGoogle Scholar
  60. 60.
    Loehberg CR, Jud SM, Haeberle L, et al. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. Breast Cancer Res Treat. 2010;121:101–10.PubMedCrossRefGoogle Scholar
  61. 61.
    Tchou J, Hou N, Rademaker A, et al. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer. 2004;100:1800–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Goldenberg VK, Seewaldt VL, Scott V, et al. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. Cancer Epidemiol Biomarkers Prev. 2007;16:1032–4.PubMedCrossRefGoogle Scholar
  63. 63.
    McKay A, Latosinsky S, Martin W. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer. 2005;103:209–10.PubMedCrossRefGoogle Scholar
  64. 64.
    Reimers LL, Campbell J, Hershman DL, et al. Uptake of selective estrogen receptor modulators and other breast cancer prevention strategies among high-risk women seen in a breast center. San Antonio Breast Cancer Symposium, 2011.Google Scholar
  65. 65.
    Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009;27:3235–58.PubMedCrossRefGoogle Scholar
  66. 66.
    Bevers TB, Armstrong DK, Arun B, et al. Breast cancer risk reduction. J Natl Compr Canc Netw. 2010;8:1112–46.PubMedGoogle Scholar
  67. 67.
    Meyskens Jr FL, Curt GA, Brenner DE, et al. Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res. 2011;4:311–23.CrossRefGoogle Scholar
  68. 68.
    Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12:496–503.PubMedCrossRefGoogle Scholar
  69. 69.
    Cuzick J, Warwick J, Pinney E, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst. 2011;103:744–52.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Epidemiology, Mailman School of Public HealthColumbia UniversityNew YorkUSA
  2. 2.Department of Medicine, College of Physicians and SurgeonsColumbia UniversityNew YorkUSA
  3. 3.Herbert Irving Comprehensive Cancer CenterColumbia UniversityNew YorkUSA

Personalised recommendations